Putnam Allstate Advisor Plus

Putnam Global Health Care Subaccount

The subaccount seeks capital appreciation.

Fund description

The subaccount seeks to capitalize on the strength of the health-care sector, targeting companies of all sizes. Holdings encompass an array of industries, including pharmaceuticals, health-care services, and biotechnology. The fund seeks companies that offer strong long-term growth prospects, regardless of their size.

Sales story

Investing in the health-care sectorA dynamic sector: From biotech to pharmaceuticals, the fund seeks out companies that profit from the global demand for health care.A range of companies: The fund invests worldwide in businesses at different stages of growth, from rapidly growing newer companies to established global corporations.Actively managed: Unlike passively managed ETFs, Putnam global sector funds combine rigorous fundamental research and disciplined quantitative analysis with macroeconomic views.

Management team

Daily pricing as of 09/22/17

with optional enhanced death benefits
Unit Value $22.629655 $22.031008
Unit Value Change 0.052981 0.051489

The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.

Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.

‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.

Quick facts as of 08/31/17

Fiscal Year End December
Asset Class Putnam Allstate Advisor Plus
Subaccount Status Open to new investors
Number of issues 56
Turnover (fiscal year end) 24%
Net Assets $151M
Inception Date 05/01/98

Performance

Performance as of 06/30/17

Annualized Performance Last Quarter Year
to Date
1 yr. 3 yrs. 5 yrs. 10 yrs. Life of
subaccount
Restated performance
Unit Value 5.25% 14.03% 8.48% 5.98% 14.63% 7.60% 5.07%
Standardized -2.75% 6.03% 0.48% 3.55% 13.93% 7.60% 5.07%
With optional enhanced death benefit
Unit Value 5.21% 13.94% 8.31% 5.82% 14.46% 7.44% 4.91%
Standardized -2.79% 5.94% 0.31% 3.39% 13.75% 7.44% 4.91%
Actual performance
Unit Value 5.25% 14.03% 8.48% 5.98% 14.63% 7.60% 4.41%
Standardized -2.75% 6.03% 0.48% 3.55% 13.93% 7.60% 4.41%
With optional enhanced death benefit
Unit Value 5.21% 13.94% 8.31% 5.82% 14.46% 7.44% 4.25%
Standardized -2.79% 5.94% 0.31% 3.39% 13.75% 7.44% 4.25%

Annual Performance at NAV

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
-2.20% -18.40% 23.99% 0.83% -2.76% 20.31% 39.40% 25.60% 6.06% -12.77%
With optional enhanced death benefit
-2.35% -18.53% 23.80% 0.67% -2.90% 20.12% 39.19% 25.41% 5.90% -12.90%

Restated performance

Monthly as of 08/31/17

Unit Value 1.02%
Standardized -6.98%

YTD as of 09/22/17

Unit Value 16.24%
Standardized 8.24%

With optional enhanced death benefit

Monthly as of 08/31/17

Unit Value 1.01%
Standardized -6.99%

YTD as of 09/22/17

Unit Value 16.11%
Standardized 8.11%

Unit values and performance information shown apply to the specific annuity product listed, not the underlying Putnam Variable Trust fund. This information should not be used by investors who hold an interest in Putnam Variable Trust funds through a different annuity or other variable product. The unit values and performance of other variable products that offer Putnam Variable Trust funds may be higher or lower due to product charges and expenses or other factors.

Data is historical. Past performance is no guarantee of future results. More recent returns may be less or more than those shown. Investment return and principal value will fluctuate, and you may have a gain or a loss when you sell your units.

Returns shown for the subaccounts for periods before their inception are derived from the historical performance of the underlying fund, adjusted to reflect the mortality, expense risk, and surrender charges applicable to this product and do not factor in the annual $30 contract maintenance fee. Additional riders and options for insurance-related charges will increase expenses and lower returns. Please see the prospectus for details. For a portion of the period, subaccounts may have limited expenses, without which returns would have been lower.

Variable annuities are long-term investments designed for retirement purposes. Putnam Hartford products are flexible-premium variable annuities issued by Hartford Life and Annuity Insurance Company, Simsbury, CT.

Putnam Allstate variable annuities are flexible-premium deferred variable annuities issued by Allstate Life Insurance Company (Allstate Life); underwritten by Allstate Distributors, L.L.C., both of Northbrook, IL; and sold through registered representatives or bank employees who are licensed insurance agents. Please check for availability in your specific state.

These policies have limitations and are sold by prospectus only. The prospectus contains details on the variable annuity, the subaccounts, contract features, fees, expenses, and other pertinent information.

Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund before investing. For a prospectus containing this and other information for any variable annuity or variable life product that invests in Putnam Variable Trust funds, contact your financial advisor for a contract prospectus and prospectus for the underlying funds. You may also call Hartford at 1-800-521-0538 or Allstate at 1-800-390-1277. Read the prospectuses carefully before investing.

For the most recent month-end performance, please call Hartford at 1-800-521-0538 or Allstate at 1-800-390-1277.

The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.

Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.

Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.

Risk Characteristics as of 08/31/17

Alpha (%) -0.74
Beta 1.09
R Squared 0.93
Standard Deviation (3 yrs.) 13.39

Holdings

Top 10 holdings as of 08/31/17

UnitedHealth Group 5.49%
Amgen 4.84%
Becton Dickinson And 4.84%
Jazz Pharmaceuticals 4.75%
Novartis Ag 4.30%
Bayer Ag 4.04%
Danaher Corp 3.96%
Johnson & Johnson 3.95%
Biogen 3.77%
Celgene Corp 3.55%
Top 10 holdings, total: 43.49%

Equity Holdings as of 06/30/17

AMGEN INC 5.88%
MERCK & CO. INC. 5.55%
UNITEDHEALTH GROUP INC 5.09%
JAZZ PHARMACEUTICALS PLC 4.92%
BECTON DICKINSON AND CO 4.71%
NOVARTIS AG-REG 4.21%
BAYER AG-REG 4.06%
JOHNSON & JOHNSON 3.93%
BIOGEN INC 3.72%
SANOFI 3.46%
DANAHER CORP 3.41%
CELGENE CORP 3.30%
ASTRAZENECA PLC 2.87%
ROCHE HOLDING AG-GENUSSCHEIN 2.85%
BOSTON SCIENTIFIC CORP 2.61%
MCKESSON CORP 2.27%
PFIZER INC 2.25%
SHIRE PLC 2.14%
AGILENT TECHNOLOGIES INC 1.92%
GILEAD SCIENCES INC 1.91%
REGENERON PHARMACEUTICALS 1.88%
DENTSPLY SIRONA INC 1.54%
INTUITIVE SURGICAL INC 1.54%
BRISTOL-MYERS SQUIBB CO 1.49%
HUMANA INC 1.44%
CLOVIS ONCOLOGY INC 1.31%
GLAXOSMITHKLINE PLC 1.30%
CHUGAI PHARMACEUTICAL CO LTD 1.29%
SHIONOGI & CO LTD 1.07%
PACIRA PHARMACEUTICALS INC 1.06%
MEDICINES COMPANY 0.98%
WALGREENS BOOTS ALLIANCE INC 0.94%
BIO-RAD LABORATORIES-A 0.83%
BIOVERATIV INC 0.79%
GRIFOLS SA-ADR 0.70%
CLINIGEN GROUP PLC 0.69%
STERICYCLE INC 0.66%
PENUMBRA INC 0.63%
AIN HOLDINGS INC 0.58%
ACLARIS THERAPEUTICS INC 0.57%
NIPPON SHINYAKU CO LTD 0.51%
ILLUMINA INC 0.50%
FRESENIUS MEDICAL CARE AG & 0.46%
CHINA BIOLOGIC PRODUCTS INC 0.45%
NEUROCRINE BIOSCIENCES INC 0.42%
AUROBINDO PHARMA LTD 0.38%
ASPEN PHARMACARE HOLDINGS LT 0.34%
ARRAY BIOPHARMA INC 0.22%
OVID THERAPEUTICS INC - RESTRICTED 0.22%
TESARO INC 0.15%
SINOPHARM GROUP CO-H 0.09%
HTG MOLECULAR DIAGNOSTICS 0.01%
NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT 0.00%

Full Portfolio Holdings as of 06/30/17

AMGEN INC 5.88%
MERCK & CO. INC. 5.55%
UNITEDHEALTH GROUP INC 5.09%
JAZZ PHARMACEUTICALS PLC 4.92%
BECTON DICKINSON AND CO 4.71%
NOVARTIS AG-REG 4.21%
BAYER AG-REG 4.06%
JOHNSON & JOHNSON 3.93%
BIOGEN INC 3.72%
SANOFI 3.46%
DANAHER CORP 3.41%
CELGENE CORP 3.30%
ASTRAZENECA PLC 2.87%
ROCHE HOLDING AG-GENUSSCHEIN 2.85%
BOSTON SCIENTIFIC CORP 2.61%
MCKESSON CORP 2.27%
PFIZER INC 2.25%
SHIRE PLC 2.14%
AGILENT TECHNOLOGIES INC 1.92%
GILEAD SCIENCES INC 1.91%
REGENERON PHARMACEUTICALS 1.88%
DENTSPLY SIRONA INC 1.54%
INTUITIVE SURGICAL INC 1.54%
BRISTOL-MYERS SQUIBB CO 1.49%
HUMANA INC 1.44%
CLOVIS ONCOLOGY INC 1.31%
GLAXOSMITHKLINE PLC 1.30%
CHUGAI PHARMACEUTICAL CO LTD 1.29%
SHIONOGI & CO LTD 1.07%
PACIRA PHARMACEUTICALS INC 1.06%
MEDICINES COMPANY 0.98%
WALGREENS BOOTS ALLIANCE INC 0.94%
BIO-RAD LABORATORIES-A 0.83%
BIOVERATIV INC 0.79%
GRIFOLS SA-ADR 0.70%
CLINIGEN GROUP PLC 0.69%
STERICYCLE INC 0.66%
PENUMBRA INC 0.63%
AIN HOLDINGS INC 0.58%
ACLARIS THERAPEUTICS INC 0.57%
NIPPON SHINYAKU CO LTD 0.51%
ILLUMINA INC 0.50%
FRESENIUS MEDICAL CARE AG & 0.46%
CHINA BIOLOGIC PRODUCTS INC 0.45%
NEUROCRINE BIOSCIENCES INC 0.42%
AUROBINDO PHARMA LTD 0.38%
ASPEN PHARMACARE HOLDINGS LT 0.34%
NEUROCRINE P/P 144A CV 02.2500 05/15/2024 0.26%
ARRAY BIOPHARMA INC 0.22%
OVID THERAPEUTICS INC - RESTRICTED 0.22%
TESARO INC 0.15%
SINOPHARM GROUP CO-H 0.09%
EUR/USD 09/20/2017 BANKAM 0.02%
CHF/USD 09/20/2017 JPMCB 0.01%
DKK/USD 09/20/2017 CITI 0.01%
HTG MOLECULAR DIAGNOSTICS 0.01%
JPY/USD 08/16/2017 CSI-FX 0.01%
AUD/USD 07/19/2017 HSBCB 0.00%
INDIAN RUPEE CALL ACCOUNT 0.00%
JAPANESE YEN CALL ACCOUNT 0.00%
NEURALSTEM INC SERIES K COMMON STOCK PURCHASE WARRANT 0.00%
POUND STERLING CALL ACCOUNT 0.00%

Prior top 10 holdings

Top 10 holdings as of 08/31/17
1: UnitedHealth Group 5.49%
2: Amgen 4.84%
3: Becton Dickinson And 4.84%
4: Jazz Pharmaceuticals 4.75%
5: Novartis Ag 4.30%
6: Bayer Ag 4.04%
7: Danaher Corp 3.96%
8: Johnson & Johnson 3.95%
9: Biogen 3.77%
10: Celgene Corp 3.55%
Holdings represent 43.49% of portfolio
Top 10 holdings as of 07/31/17
1: UnitedHealth Group 5.30%
2: Becton Dickinson And 4.90%
3: Jazz Pharmaceuticals 4.89%
4: Amgen 4.76%
5: Novartis Ag 4.34%
6: Bayer Ag 4.01%
7: Biogen 3.99%
8: Johnson & Johnson 3.96%
9: Danaher Corp 3.87%
10: Sanofi 3.47%
Holdings represent 43.49% of portfolio
Top 10 holdings as of 06/30/17
1: Amgen 5.88%
2: Merck 5.55%
3: UnitedHealth Group 5.09%
4: Jazz Pharmaceuticals 4.92%
5: Becton Dickinson And 4.71%
6: Novartis Ag 4.21%
7: Bayer Ag 4.06%
8: Johnson & Johnson 3.93%
9: Biogen 3.72%
10: Sanofi 3.46%
Holdings represent 45.53% of portfolio
Top 10 holdings as of 05/31/17
1: Merck 5.77%
2: Amgen 5.42%
3: Celgene Corp 4.80%
4: Becton Dickinson And 4.68%
5: Bayer Ag 4.27%
6: Novartis Ag 4.24%
7: Jazz Pharmaceuticals 4.08%
8: Johnson & Johnson 3.90%
9: UnitedHealth Group 3.78%
10: Sanofi 3.66%
Holdings represent 44.60% of portfolio

Portfolio Composition as of 08/31/17

Common stock 98.49%
Cash and net other assets 1.22%
Convertible bonds 0.29%

Portfolio allocations vary over time. The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.

Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.

Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.

Top Industry Sectors as of 08/31/17

Pharmaceuticals 40.88%
Biotechnology 26.48%
Health Care Equipment & Supplies 16.40%
Health Care Providers & Services 9.20%
Life Sciences Tools & Services 3.79%
Food & Staples Retailing 1.76%
Cash and net other assets 1.22%
Diversified Financial Services 0.26%
Health Care Technology 0.01%

Country Allocation as of 08/31/17

United States 71.06%
Switzerland 7.33%
United Kingdom 6.58%
Germany 4.49%
Japan 3.59%
France 3.53%
Cash and net other assets 1.22%
Spain 0.69%
China 0.49%
 
Other
1.02%
India 0.41%
South Africa 0.35%
Ireland 0.26%

Expenses

Sales Charges/Fees

Breakpoint Sales Charge Dealer Allowance CDSC Liab
$0 - $0 0.00% 0.00% N

The fund concentrates its investments in one region or in one sector and involves more risk than a fund that invests more broadly. Variable annuities are long-term investments designed for retirement purposes. Withdrawals prior to age 59 1/2 may be subject to a 10% IRS penalty.

Growth investing targets companies with above-average earnings that may be subject to price volatility if earnings expectations are not met.

‡ Lipper is an industry research firm whose rankings are based on total return performance, vary over time, and do not reflect the effects of sales charges. Past performance is not indicative of future results.

CDSC

Year Percent
1 8.00%
2 8.00%
3 8.00%
4 7.00%
5 6.00%
6 5.00%
7 4.00%
8 3.00%
9+ 0.00%